VVUS hits a bottom. Breaking out of falling wedge formation

98 0 0
- Qysmia looks to be gaining from new online marketing efforts
- Endo             will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS            

PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)

Disclosure: Long $2 Jan 2017 calls @1.10/contract
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out